VTVT Latest Press Releases

-- October 27, 2026 --

vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems Globe Newswire 8:00 AM

-- October 15, 2026 --

iOnctura appoints Paul Sekhri as Chair of its Board of Directors Globe Newswire 3:30 AM

-- October 10, 2026 --

vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 Globe Newswire 8:00 AM

-- October 7, 2026 --

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease Globe Newswire 4:01 PM

-- October 6, 2026 --

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026 Globe Newswire 8:00 AM

-- October 5, 2026 --

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) Globe Newswire 8:00 AM

-- September 15, 2026 --

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- September 2, 2026 --

vTv Therapeutics to Participate in September Investor Conferences Globe Newswire 8:00 AM

-- August 19, 2026 --

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 6, 2026 --

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 8:00 AM

-- July 28, 2026 --

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 2, 2026 --

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 2, 2026 --

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes